Janney Montgomery Scott LLC bought a new stake in CareDx, Inc. (NASDAQ:CDNA - Free Report) in the first quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm bought 21,148 shares of the company's stock, valued at approximately $375,000.
Other hedge funds and other institutional investors also recently bought and sold shares of the company. Sterling Capital Management LLC lifted its holdings in CareDx by 771.2% in the fourth quarter. Sterling Capital Management LLC now owns 1,272 shares of the company's stock valued at $27,000 after acquiring an additional 1,126 shares during the period. Tower Research Capital LLC TRC lifted its holdings in CareDx by 553.7% in the fourth quarter. Tower Research Capital LLC TRC now owns 3,922 shares of the company's stock valued at $84,000 after acquiring an additional 3,322 shares during the period. State of Wyoming acquired a new stake in CareDx in the fourth quarter valued at $91,000. IQ EQ FUND MANAGEMENT IRELAND Ltd lifted its holdings in CareDx by 41.5% in the fourth quarter. IQ EQ FUND MANAGEMENT IRELAND Ltd now owns 9,343 shares of the company's stock valued at $200,000 after acquiring an additional 2,742 shares during the period. Finally, KLP Kapitalforvaltning AS acquired a new stake in CareDx in the fourth quarter valued at $208,000.
Wall Street Analyst Weigh In
CDNA has been the subject of several research reports. HC Wainwright reaffirmed a "neutral" rating and set a $25.00 price target on shares of CareDx in a research note on Monday, May 5th. Wall Street Zen cut CareDx from a "buy" rating to a "hold" rating in a report on Monday, May 5th. Stephens reiterated an "overweight" rating and set a $40.00 target price on shares of CareDx in a report on Monday, May 5th. Finally, The Goldman Sachs Group reduced their price target on CareDx from $34.00 to $26.00 and set a "buy" rating on the stock in a research report on Thursday, April 17th. Three research analysts have rated the stock with a hold rating and four have assigned a buy rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and a consensus price target of $30.33.
View Our Latest Stock Analysis on CareDx
CareDx Price Performance
CareDx stock traded up $0.80 during mid-day trading on Tuesday, hitting $19.25. The company's stock had a trading volume of 729,031 shares, compared to its average volume of 919,901. The firm's 50 day moving average is $17.81 and its 200 day moving average is $19.71. The company has a market cap of $1.07 billion, a PE ratio of 16.74 and a beta of 2.19. CareDx, Inc. has a 52-week low of $14.09 and a 52-week high of $34.84.
CareDx (NASDAQ:CDNA - Get Free Report) last released its earnings results on Wednesday, April 30th. The company reported $0.09 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.06 by $0.03. CareDx had a return on equity of 21.16% and a net margin of 19.79%. The firm had revenue of $84.69 million for the quarter, compared to analyst estimates of $84.56 million. During the same quarter last year, the firm posted ($0.03) EPS. The company's revenue was up 17.6% on a year-over-year basis. As a group, analysts forecast that CareDx, Inc. will post -0.9 EPS for the current year.
Insider Buying and Selling
In related news, Director Peter Maag sold 10,000 shares of the stock in a transaction that occurred on Tuesday, June 17th. The stock was sold at an average price of $19.24, for a total transaction of $192,400.00. Following the completion of the transaction, the director directly owned 318,846 shares of the company's stock, valued at approximately $6,134,597.04. This represents a 3.04% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, Director William A. Hagstrom sold 19,391 shares of the company's stock in a transaction that occurred on Wednesday, June 11th. The shares were sold at an average price of $19.90, for a total value of $385,880.90. Following the completion of the sale, the director owned 53,979 shares in the company, valued at $1,074,182.10. This represents a 26.43% decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 129,078 shares of company stock worth $2,234,115. Company insiders own 4.40% of the company's stock.
About CareDx
(
Free Report)
CareDx, Inc engages in the discovery, development, and commercialization of diagnostic solutions for transplant patients and caregivers in the United States and internationally. It also provides AlloSure Kidney, a donor-derived cell-free DNA (dd-cfDNA) solution for kidney transplant patients; AlloMap Heart, a gene expression solution for heart transplant patients; AlloSure Heart, a dd-cfDNA solution for heart transplant patients; and AlloSure Lung, a dd-cfDNA solution for lung transplant patients.
See Also
Before you consider CareDx, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and CareDx wasn't on the list.
While CareDx currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
